These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35558166)

  • 21. Brexanolone for the treatment of patients with postpartum depression.
    Morrison KE; Cole AB; Thompson SM; Bale TL
    Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.
    Lüscher B; Möhler H
    F1000Res; 2019; 8():. PubMed ID: 31275559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
    Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
    Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
    Faden J; Citrome L
    Ther Adv Psychopharmacol; 2020; 10():2045125320968658. PubMed ID: 33224470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions.
    Patterson R; Balan I; Morrow AL; Meltzer-Brody S
    Neuropsychopharmacology; 2024 Jan; 49(1):67-72. PubMed ID: 37715106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brexanolone therapeutics in post-partum depression involves inhibition of systemic inflammatory pathways.
    Balan I; Patterson R; Boero G; Krohn H; O'Buckley TK; Meltzer-Brody S; Morrow AL
    EBioMedicine; 2023 Mar; 89():104473. PubMed ID: 36801618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond.
    Zorumski CF; Paul SM; Covey DF; Mennerick S
    Neurobiol Stress; 2019 Nov; 11():100196. PubMed ID: 31649968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allopregnanolone: From molecular pathophysiology to therapeutics. A historical perspective.
    Paul SM; Pinna G; Guidotti A
    Neurobiol Stress; 2020 May; 12():100215. PubMed ID: 32435665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allopregnanolone-based treatments for postpartum depression: Why/how do they work?
    Walton N; Maguire J
    Neurobiol Stress; 2019 Nov; 11():100198. PubMed ID: 31709278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression.
    Rudzinskas SA; Mazzu MA; Schiller CE; Meltzer-Brody S; Rubinow DR; Schmidt PJ; Goldman D
    Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression.
    Powell JG; Garland S; Preston K; Piszczatoski C
    Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884
    [No Abstract]   [Full Text] [Related]  

  • 34. Biomarkers and treatments for mood disorders encompassing the neurosteroid and endocannabinoid systems.
    Pinna G
    J Neuroendocrinol; 2023 Feb; 35(2):e13226. PubMed ID: 36625096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brexanolone to Treat Postpartum Depression in Adult Women.
    Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allopregnanolone Concentrations in Breast Milk and Plasma from Healthy Volunteers Receiving Brexanolone Injection, With Population Pharmacokinetic Modeling of Potential Relative Infant Dose.
    Wald J; Henningsson A; Hanze E; Hoffmann E; Li H; Colquhoun H; Deligiannidis KM
    Clin Pharmacokinet; 2022 Sep; 61(9):1307-1319. PubMed ID: 35869362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of fast-acting antidepressant drugs on a postpartum depression mice model.
    García-Baos A; Gallego-Landin I; Ferreres-Álvarez I; Puig-Reyne X; Castro-Zavala A; Valverde O; Martín-Sánchez A
    Biomed Pharmacother; 2022 Oct; 154():113598. PubMed ID: 36029538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurosteroids and translocator protein 18 kDa (TSPO) ligands as novel treatment options in depression.
    Riebel M; Brunner LM; Nothdurfter C; Wein S; Schwarzbach J; Liere P; Schumacher M; Rupprecht R
    Eur Arch Psychiatry Clin Neurosci; 2024 Jul; ():. PubMed ID: 38976049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Realising the therapeutic potential of neuroactive steroid modulators of the GABA
    Belelli D; Hogenkamp D; Gee KW; Lambert JJ
    Neurobiol Stress; 2020 May; 12():100207. PubMed ID: 32435660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations.
    Leader LD; O'Connell M; VandenBerg A
    Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.